close_game
close_game

Nosebleed drug could be crash saviour

Hindustan Times | By, New Delhi
Mar 23, 2011 11:58 PM IST

Giving tranexamic acid, an anti-fibrinolytic drug used to stop nosebleeds, within three to eight hours of injury can save the life of 12,500 of the 85,000 people who bleed to death in road traffic accidents in India each year, reports a study in The Lancet.

Giving tranexamic acid, an anti-fibrinolytic drug used to stop nosebleeds, within three to eight hours of injury can save the life of 12,500 of the 85,000 people who bleed to death in road traffic accidents in India each year, reports a study in The Lancet.

HT Image
HT Image

Over 4,760 patients and their families from 84 hospitals across India participated in this study, which involved 20,211 accident victims across 40 countries.

Road traffic accidents — and not AIDS, cancer, malaria or any other disease — are the leading cause of death among young people between 10 and 24 years, according to the World Health Organisation (WHO). Of the 1.2 million road accident deaths each year, nearly 400,000 victims are under the age of 25.

“The drug is very cheap and easily available throughout the country...,” said Dr Yashbir Dewan, lead coordinator for the study.

Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
See More
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
SHARE THIS ARTICLE ON
SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Wednesday, February 12, 2025
Start 14 Days Free Trial Subscribe Now
Follow Us On